fr en es de it pt nl

Reactivos e instrumentos para inmunología, biología celular y biología molecular.

Temozolomide [85622-93-1]

Imprimir

Referencia B1399-10mg

embalaje : 10mg

Contact local distributor :

Teléfono : +1 850 650 7790

Marca : APExBIO Technology

Contact local distributor :

Teléfono : +1 850 650 7790

<div class="message global noscript"><div class="content"><p><strong>JavaScript seems to be disabled in your browser.</strong> <span>For the best experience on our site, be sure to turn on Javascript in your browser.</span></p></div></div>

Background

Temozolomide, an alkylating agent, is a DNA damage inducer.

Product Citation

1. Fanchu Zeng, Zhijin Fan, et al. "Tumor Microenvironment Activated Photoacoustic-Fluorescence Bimodal Nanoprobe for Precise Chemo-immunotherapy and Immune Response Tracing of Glioblastoma." ACS Nano. 2023 Oct 24;17(20):19753-19766. PMID: 37812513
2. Schwartz, Hannah, et al. "In vitro Methods to Better Evaluate Drug Responses in Cancer." UMass Chan Medical School. September 8, 2022.

Chemical Properties

Physical Appearance	A solid
Storage	Store at -20°C, sealed storage, away from moisture and light
M.Wt	194.15
Cas No.	85622-93-1
Formula	C6H6N6O2
Solubility	insoluble in EtOH; insoluble in H2O; ≥29.61 mg/mL in DMSO
Chemical Name	3-methyl-4-oxoimidazo [5,1-d] [1,2,3,5] tetrazine-8-carboxamide
SDF	Download SDF
Canonical SMILES	CN1C(=O)N2C=NC(=C2N=N1)C(=O)N
Shipping Condition	Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips	We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment [1]:
Cell lines	SK-LMS-1 leiomyosarcoma (MGMT-/p53+), Ewing sarcoma A-673 and GIST-T1 (both lines with MGMT+/p53- phenotype), and glioblastoma T98G (MGMT+/p53+)
Preparation method	The solubility of this compound in DMSO is >6.6 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting condition	62.5, 125, 250 and 500 μM; 72 h
Applications	In SK-LMS-1 cells, Temozolomide inhibited proliferative activity of SK-LMS-1 cells. A-673 cells was most sensitive to temozolomide, the effect was time- and dose-dependent. Preincubation of Ewing sarcoma cells with O6-benzylguanine potentiated the cytotoxic effect of the alkylating agent and reduced viability of tumor cells. GIST-T1 cells were insensitive to temozolomide.
Animal experiment [2]:
Animal models	PARP1 wild‐type (WT) and PARP1 knock‐out (KO) mice
Dosage form	68 mg/kg; once daily for 5 days; orally administrated
Application	In PARP1 WT mice, temozolomide significantly lowered concentrations of NAD+ in the liver when compared with the control group (by 22%, p = 0.02). In the livers of PARP1 KO mice, there was also a statistically significant reduction in NAD+ in the temozolomide‐only group when compared with the control (by 22%, p = 0.03).
Other notes	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References: [1] Khusnutdinov RR1, Boichuk SV2. Mechanisms of Sensitivity of Soft Tissue Sarcoma Cells to Temozolomide. Bull Exp Biol Med. 2017 Jul 18. [2] Almeida GS1, Bawn CM1, Galler M1, et al. PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. NMR Biomed. 2017 May 22.

Quality Control

Purity = 98.69%

Chemical structure

Temozolomide

Usted podría estar interesado también en los siguientes productos:

Referencia

Descripción

Cond.

Precio Sin IVA

T1178-50mg

Temozolomide [85622-93-1]

50mg